Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$727 Mln
P/E Ratio
--
P/B Ratio
7
Industry P/E
--
Debt to Equity
0.66
ROE
-0.1 %
ROCE
-5.9 %
Div. Yield
0 %
Book Value
2.36
EPS
-0.23
CFO
$-126.49 Mln
EBITDA
$-161.32 Mln
Net Profit
$-209.36 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Axogen Inc (AXGN)
| -0.49 | -9.64 | -9.59 | 138.72 | 31.09 | 14.45 | 17.18 |
|
BSE Sensex*
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Axogen Inc (AXGN)
| 139.56 | -31.56 | 6.51 | -47.65 | 0.06 | -12.43 | -27.68 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.93 | 10,562.04 | 12.43 | 12.69 | |
| 72.80 | 10,050.19 | 97.07 | 2.52 | |
| 163.74 | 8,847.72 | -- | -25.23 | |
| 299.78 | 11,550.00 | 278.74 | 3.65 |
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human... nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida. Read more
Chairman, President & CEO
Ms. Karen Zaderej
Chairman, President & CEO
Ms. Karen Zaderej
Headquarters
Alachua, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Axogen Inc (AXGN) stood at $ 204 Mln as on 31-Dec-24
The share price of Axogen Inc (AXGN) is $16.40 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Axogen Inc (AXGN) has given a return of 31.09% in the last 3 years.
Axogen Inc (AXGN) has a market capitalisation of $ 727 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Axogen Inc (AXGN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Axogen Inc (AXGN) and enter the required number of quantities and click on buy to purchase the shares of Axogen Inc (AXGN).
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.
The CEO & director of Ms. Karen Zaderej. is Axogen Inc (AXGN), and CFO & Sr. VP is Ms. Karen Zaderej.
There is no promoter pledging in Axogen Inc (AXGN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,078
|
|
|
1,054
|
|
|
964
|
|
|
853
|
| Axogen Inc (AXGN) | Ratios |
|---|---|
|
Return on equity(%)
|
-9.99
|
|
Operating margin(%)
|
-0.94
|
|
Net Margin(%)
|
-5.32
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Axogen Inc (AXGN) was $0 Mln.
$0.24
(
